Riders · The University of Texas M.D. Anderson Cancer Center · Article III: Agencies of Education
Rare and Aggressive Breast Cancer Research Program
Rider 8 in the 2026-27 Act, page III-239
2028-29 request. The University of Texas M.D. Anderson Cancer Center's request has a row with this rider's number. What that row asks could not be checked, so it is not shown. The agency's request.
Through the session
- 2024-25 Act In current law rider 8
- Introduced (Senate) Amended rider 7
- Introduced (House) Amended rider 7
- Senate substitute Unchanged rider 7
- House substitute Unchanged rider 7
- House passed Unchanged rider 7
- Conference Unchanged rider 8
- 2026-27 Act Unchanged rider 8
Pick any two steps to compare their wording.
What changed in the text
2024-25 Act → Introduced (House): 3 passages changed.
Removed words are struck through; added words are underlined. Sources: 2024-25 Act · Introduced (House).
Every version: numbers, statuses and source pages
| Version | Rider | Against the version before | Against the current budget | Source |
|---|---|---|---|---|
| 2024-25 ActGeneral Appropriations Act, 2024-25 Biennium | 8 | First version | — | Page III-213 |
| Introduced (Senate)Senate Bill 1 as introduced (LBB recommended, Senate) | 7 was 8 | Amended | — | Page III-210 |
| Introduced (House)House Bill 1 as introduced (LBB recommended, House) | 7 was 8 | Amended | — | Page III-209 |
| Senate substituteCommittee Substitute for Senate Bill 1 | 7 | Unchanged | Amended | Page III-199 |
| House substituteHouse Committee Substitute for Senate Bill 1 | 7 | Unchanged | Amended | Page III-202 |
| House passedSenate Bill 1 as passed the second house | 7 | Unchanged | Amended | Page III-202 |
| ConferenceConference Committee Report for Senate Bill 1 | 8 was 7 | Unchanged | Amended | Page III-215 |
| 2026-27 ActGeneral Appropriations Act, 2026-27 Biennium | 8 | Unchanged | Amended | Page III-239 |
Full text of each wording
Introduced (Senate), Introduced (House), Senate substitute, House substitute, House passed, Conference, 2026-27 Act
Source, page III-239Rare and Aggressive Breast Cancer Research Program. Of the amounts appropriated above in Strategy D.1.2, Breast Cancer Research Program, $2,000,000 in fiscal year 2026 and $2,000,000 in fiscal year 2027 from the General Revenue Fund is for the rare and aggressive breast cancer research program. Its efforts will contribute to improving the diagnostics in patients with breast cancer.
2024-25 Act
Source, page III-213Rare and Aggressive Breast Cancer Research Program. Of the amounts appropriated above in Strategy D.1.2, Breast Cancer Research Program, $2,000,000 in fiscal year 2024 and $2,000,000 in fiscal year 2025 in General Revenue is for the rare and aggressive breast cancer research program. Its efforts will contribute to improving the diagnostics in patients with breast cancer.